Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)



Status:Recruiting
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:6 - 16
Updated:3/31/2019
Start Date:February 22, 2016
End Date:November 2020
Contact:Elizabeth Hartigan, RN
Email:elizabeth.hartigan@chp.edu
Phone:412-692-7060

Use our guide to learn which trials are right for you!

Vitamin D to Prevent Severe Asthma Exacerbations

This study will determine whether vitamin D3 prevents severe asthma attacks in children who
have a serum vitamin D (25(OH)D) level <30 ng/ml and who are being treated with inhaled
corticosteroids for asthma. Half the participants will receive vitamin D3 at a dose of 4,000
IU/day, and the other half will receive placebo.

Results from experimental studies, observational studies, two small trials, and a recent
meta-analysis suggest that vitamin D reduces the risk of severe asthma exacerbations, and
that this protective effect may be due to immune modulation of viral illnesses and/or
increased response to inhaled corticosteroids (ICS).

On the basis of those findings, the investigators hypothesize that vitamin D reduces the
incidence of severe asthma exacerbations in high-risk school-aged children who have a serum
vitamin D level <30 ng/ml and who are being treated with ICS for persistent asthma. The
investigators further hypothesize that this protective effect results from reduced incidence
of common viral illnesses or enhanced response to ICS. These hypotheses will be tested in a
48-week randomized double-masked placebo-controlled trial of vitamin D3 supplementation to
prevent severe asthma exacerbations in 400 children aged 6 to 16 years who have vitamin D
insufficiency or deficiency (a serum 25(OH)D <30 ng/ml) and experienced a severe exacerbation
in the prior year (a marker of high risk for subsequent events), and who (after a run-in
period) are well controlled on medium-dose inhaled corticosteroids.

Our primary aim will determine whether vitamin D3 (4,000 IU/day) reduces the risk of severe
asthma exacerbations (our primary outcome) in participating children. Secondary aims will
determine the efficacy of vitamin D3 supplementation in: 1) preventing severe asthma
exacerbations due to viral infections, 2) reducing the daily and average cumulative dose of
inhaled corticosteroids.

Study participation involves 8-9 visits, with each visit lasting between 30-90 minutes.
Participation requires completion of study questionnaires, spirometry (breathing tests), and
collection of blood samples (to measure vitamin D levels) and urine samples (to measure
urinary calcium/creatinine ratios) at some study visits. Since the start of the study,
vitamin D levels and urinary calcium/creatinine ratios have been simultaneously measured, to
monitor for both vitamin D toxicity and high risk of severe vitamin D deficiency or rickets,
which (should they occur) would be managed by a pediatric endocrinologist or a pediatric
nephrologist, as appropriate.

All safety data for the study is regularly reviewed by a Data Safety Monitoring Board
appointed by the National Heart, Lung and Blood Institute, as well as by the Institutional
Review Board of each participating institution. Total study participation will last about one
year.

Inclusion Criteria:

- 6 to 16 years old

- Physician-diagnosed asthma for at least one year

- At least one severe asthma exacerbation in the previous year

- Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor]
or inhaled β2-agonist [at least three days per week]) for at least six months in the
previous year

- Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level <30 ng/ml (75 nmol/L))

- FEV1 ≥70 % of predicted

- Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after
inhaled short acting beta agonist or increased airway responsiveness to methacholine
(PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)

- Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma
controller medications) approved by the child's regular doctor

- Parental consent and child's assent to participate in the study.

Additional inclusion criteria applied after the run-in period, to be eligible for
randomization:

- Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the
run-in period

- Willingness to be randomized and complete study

Exclusion Criteria:

- Serum calcium >10.8 mg/dl

- Serum 25(OH) D <14 ng/ml (35 nmol/L)

- Chronic respiratory disorder other than asthma

- Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in
previous year OR ≥6 severe asthma exacerbations in previous year)

- Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect
vitamin D metabolism

- Current smoking, or former smoking if ≥5 pack-years

- Immune deficiency, cleft palate or Down's syndrome

- Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3

- Chronic oral corticosteroid therapy

- Inability to perform acceptable spirometry

- Use of investigational therapies or participation in trials 30 days before or during
the study

- Participant is currently breast feeding an infant

- Pregnancy

- Weight less than 10 kg

- Plans to move out of the study site area in the next year

Additional exclusion criteria applied after the run-in period:

- Any severe asthma exacerbation during the run-in period

- Need for asthma medications other than ICS and p.r.n. rescue inhalers during the
run-in period
We found this trial at
7
sites
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Juan C Celedon, MD, DrPH
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Theresa W. Guilbert, MD
Phone: 513-636-1882
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-1000
Principal Investigator: Kristie Ross, MD
Phone: 216-844-7927
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Wanda Phipatanakul, MD, MS
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
1400 Jackson St
Denver, Colorado 80206
(303) 388-4461
Principal Investigator: Ronina Covar, MD
Phone: 303-398-1417
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Leonard Bacharier, MD
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Michael Cabana
?
mi
from
San Francisco, CA
Click here to add this to my saved trials